Enovis (NYSE:ENOV) Given New $40.00 Price Target at Wells Fargo & Company

Enovis (NYSE:ENOV) had its price target reduced by Wells Fargo & Company from $42.00 to $40.00 in a report issued on Friday,Benzinga reports. They currently have an overweight rating on the stock.

ENOV has been the topic of a number of other research reports. Wall Street Zen cut shares of Enovis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Evercore reaffirmed an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. Zacks Research raised shares of Enovis from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 4th. Needham & Company LLC boosted their target price on shares of Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Finally, BTIG Research boosted their target price on shares of Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $45.17.

Enovis Stock Down 2.7%

Shares of ENOV opened at $26.52 on Friday. Enovis has a one year low of $21.00 and a one year high of $37.85. The company has a market cap of $1.53 billion, a P/E ratio of -1.33 and a beta of 1.41. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.04. The firm has a 50 day simple moving average of $23.86 and a two-hundred day simple moving average of $25.80.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.89 EPS for the quarter, beating the consensus estimate of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The business had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. During the same period in the previous year, the business earned $0.81 earnings per share. The company’s revenue was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Research analysts forecast that Enovis will post 3.62 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Oliver Engert acquired 1,000 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were purchased at an average price of $25.50 per share, for a total transaction of $25,500.00. Following the completion of the acquisition, the insider owned 43,640 shares of the company’s stock, valued at approximately $1,112,820. This trade represents a 2.35% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have acquired a total of 5,000 shares of company stock worth $121,983 over the last quarter. Corporate insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Enovis

Several institutional investors have recently made changes to their positions in ENOV. AQR Capital Management LLC raised its holdings in shares of Enovis by 12.5% in the 1st quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock worth $2,363,000 after acquiring an additional 7,072 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Enovis by 37.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock worth $10,226,000 after acquiring an additional 73,116 shares during the last quarter. Empowered Funds LLC raised its holdings in shares of Enovis by 13.0% in the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after acquiring an additional 749 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after acquiring an additional 707 shares during the last quarter. Finally, Amundi raised its holdings in shares of Enovis by 24,405.0% in the 2nd quarter. Amundi now owns 9,802 shares of the company’s stock worth $328,000 after acquiring an additional 9,762 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis News Roundup

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported first-quarter EPS of $0.89, topping estimates of $0.82, while revenue of $589.15 million also beat expectations. Revenue rose 5.4% year over year, signaling solid demand and execution. Article Title
• Positive Sentiment: The company reaffirmed 2026 free cash flow conversion of greater than 25%, suggesting management still sees healthy cash generation despite Middle East and tariff headwinds. Article Title
• Neutral Sentiment: Enovis also reiterated full-year 2026 guidance, with EPS of $3.52 to $3.73 and revenue of $2.3 billion to $2.4 billion, which was roughly in line with analyst expectations and may reassure investors about the company’s near-term outlook. Article Title
• Neutral Sentiment: Wells Fargo lowered its price target on Enovis to $40 from $42, but kept an overweight rating, indicating continued upside potential despite a slightly more cautious valuation view. Article Title

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.